Deals channel feed – Endpoints News

Deals channel feed

The IFM team sets up a three-peat as Novartis funds cGAS/STING program — with $840M option to buy

6 years ago

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

6 years ago

Vertex gambles $950M on biotech buyout, hunting a cure for diabetes

6 years ago

Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?

6 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

6 years ago

Immatics scores $75M upfront in TCR deal with Celgene as interest in tech burgeons

6 years ago

Adaptimmune pledges $312M for Noile-Immune's T cell boosting tech in drive to deliver on TCR promise

6 years ago

Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps

6 years ago

GSK licenses Ionis' experimental hep B treatments in up to $262M deal

6 years ago

From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months

6 years ago

Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene

6 years ago

Why would Amgen want to buy Alexion? Analysts call hotly rumored takeover unlikely, but seize the moment

6 years ago

Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent

6 years ago

Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication'

6 years ago

Elanco to buy Bayer's animal health business for $7.6B, as dealmaking gathers steam in the sector

6 years ago

On the cusp of PhI, Angelman-focused biotech scores potential buyout deal from Ultragenyx

6 years ago

As investors fret about Xyrem durability, Jazz spends $52M+ upfront to swallow neuro-focused biotech

6 years ago

As disaster struck, AbbVie’s Rick Gonzalez swooped in on Allergan with an offer Brent Saunders couldn’t say no to

6 years ago

Plugging in the last piece to its gene therapy puzzle, AskBio acquires Scottish synthetic promoter company

6 years ago

Novartis offloads a late-stage PI3Kẟ rare disease program in a discount deal

6 years ago

Boehringer follows the popular KRAS trail to MD Anderson — inks new alliance on 'virtual' research center

6 years ago

BridgeBio CEO Neil Kumar engineers a deal to reel back Eidos shares. Or is he really hunting a buyout?

6 years ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

6 years ago

Bayer is going all in on next-gen stem cell biotech BlueRock, buying out Versant and founders for $600M

6 years ago

First page Previous page 99 100 101102103 104 105 Next page Last page